Tag: BF Biosciences

  • BF Biosciences Launches Zeptide® (Tirzepatide) in Pakistan — A Major Step in Diabetes and Obesity Care

    BF Biosciences Limited, Pakistan’s pioneering biopharmaceutical manufacturer, has announced the successful launch of its latest innovation, Zeptide® (Tirzepatide) — an advanced treatment for Type 2 Diabetes and Obesity, now available in a convenient, pre-filled syringe format.

    In a notice sent to PSX today, BFBIO says that Tirzepatide, approved by the US Food and Drug Administration (FDA), is a synthetic polypeptide that acts as a dual agonist for GLP-1 and GIP receptors, offering a breakthrough approach in managing blood glucose levels and promoting weight reduction.

    The new Zeptide® pre-filled syringe, developed and produced at BF Biosciences’ state-of-the-art European technology-based facility, ensures precision, safety, and ease of use, eliminating dosing errors and improving patient compliance.

     “With Zeptide®, we are proud to bring a world-class therapeutic option to Pakistani patients,” said a company spokesperson. “This innovation reinforces our commitment to developing essential, locally manufactured biologics that meet international quality standards.”

    Zeptide® has undergone rigorous testing for quality, structure, and potency at a leading biological mass spectrometry facility in the United States and at a national university in Pakistan, ensuring global-level validation.

    The development of Zeptide® is a significant milestone achieved through the company’s IPO proceeds utilization plan, demonstrating BF Biosciences’ dedication to reinvesting in Pakistan’s healthcare ecosystem.

    With Pakistan ranking among the highest globally in diabetes prevalence, the need for accessible and effective treatment options is urgent. Over 9 million Pakistanis remain undiagnosed, while 57% of women and 41% of men are overweight or obese, increasing their risk of Type 2 diabetes by up to seven times.

    It is pertinent to mention that BF Biosciences Limited is already leading the GLP1 generic of semaglutide through its brand Sematide and is most prescribed GLP1 in the market.

    As the 1st Biopharmaceutical Plant in Pakistan, BF Biosciences Limited has remained committed to the production of essential medicines for the treatment of HCV, Cancer, Cardiology, Diabetes, nephrology and other therapeutic areas for over a decade. We are confident that the launch of Zeptide® will have a positive impact on the Company’s growth and will further strengthen our mission to address critical, unmet patient needs, the notice further added.

    Also Read: Mobilink Bank Bags Four Awards at AMC-9 for Digital Innovation and Financial Inclusion

  • BF Biosciences IPO General Subscription on 2nd and 3rd October!

    The general public will subscribe 6.25 million shares, 25 percent of the total offer size of BF Biosciences IPO on October 2nd and 3rd at the strike price of Rs 77.

    The general public can subscribe the IPO on 2nd and 3rd October from 9.00 am to 5pm during banking hours. However, in the case of e-IPO, the process continues for 24 hours.

    The book-building phase of BF Biosciences concluded last week with an oversubscription of 3.4 times.

    The IPO received an overwhelming response from institutional investors and high-net worth individuals as the strike price clocked in at Rs 77/share, 40 percent higher than the floor price of Rs 55 and raised Rs 1.93 billion.

    Shahid Ali, CEO Arif Habib Limited said that investing in the public offering of BF Biosciences presents a decent opportunity for retail investors to engage with a fundamentally strong company at a more attractive valuation compared to the broader pharmaceutical sector.

    This unique positioning allows investors to capitalize on potential growth while benefiting from a favorable entry point.

    Also Read: Yousaf Hussain Takes Over as OICCI President for 2024-2026 Term

  • BF Biosciences IPO Receives Overwhelming Response from Investors!

    BF Biosciences IPO oversubscribed by 3.4 times!

    The book-building process of BF Biosciences’ Initial Public Offer (IPO) has concluded with an oversubscription of 3.40 times, the company said on Thursday.

    The IPO received an overwhelming response from institutional investors and high-net worth individuals as the strike price clocked in at Rs 77/share, a max 40% higher than the floor price of Rs55.

    BF Biosciences has raised Rs 1.93 billion in total, making it the first Pharma sector IPO in 2024.

    Several brokerages had had issued almost unanimous calls to ‘subscribe,’ which resulted in investor demand amounting to Rs 4.7 billion against the IPO’s book-building size of Rs 1.375 billion.

    The general public will subscribe to 6.25 million shares (25 percent of the total offer size) on October 2nd and 3rd at the strike price of Rs 77.

    Farhan Rafiq, COO BF Biosciences in his message thanked investors for their overwhelming response and vowed to ensure growth of their shareholders’ equity.

    This strategic initiative is expected to drive significant growth in both the company’s top line and profitability as company has already completed a brownfield expansion and IPO will also help the company to manage working capital needs of the aforesaid expansion.

    Shahid Ali, CEO Arif Habib Limited, the lead manager and book runner to the issue said that IPO of BF Biosciences received an exceptional response, with an impressive participation of Rs. 4.7 billion. This marks a significant milestone, as it has been a considerable time since an IPO has garnered such overwhelming interest, achieving an oversubscription of 3.4 times and a premium of 40% over its floor price.

    Also Read: IMF deal should bring 12% interest rate, Rs25 per unit electricity: S M Tanveer

  • BF Biosciences Book Building Starts today (25 September)

    BF Biosciences IPO’s book building phase will be held on 25th and 26th September where high net worth individuals and institutional investors will subscribe to 100 per cent of the issue size.

    BF Biosciences, a leader in the biotech pharmaceuticals sector in Pakistan, is set to raise between Rs1.38 and Rs1.93 billion to expand its key product lines and obtain export certifications.

    The floor price for the issue has been set at Rs55 per share through a 100 percent book building process.

    The unsubscribed shares, if any, of the general subscription portion would be allocated to the successful bidders of the book building portion on a pro-rata basis. The issuer will utilize any additional funds raised above the floor price in managing its additional requirements for capex and working capital needs.

    BF Biosciences has estimated that the maximum strike price for the IPO may climb to Rs77 per share that would increase the funds raised to Rs1.93 billion.

    This strategic initiative is expected to drive significant growth in both the company’s top line and profitability as company has already completed a brownfield expansion and IPO will also help the company to manage working capital needs of the aforesaid expansion.

    Arif Habib Limited has been appointed as a lead manager and book runner to the issue.

    Also Read: Spotify announces Nusrat Fateh Ali Khan as the first artist for ICON Pakistan